The FDA Commissioner recently traveled to India to express the agency’s reservations over shortcomings involving the processes used by several of India’s drug manufacturers. The visit also highlighted the challenges Washington perceives from India’s growing domestic biopharma industry. (For more on the visit, click here.)

Poll Question:
Do you think the U.S. concern over pharmaceutical manufacturing operations in India might be more motivated by competitive issues rather than quality control problems?



Previous articleEpigenetic Factor Revealed as Weak Link in Malaria Transmission
Next articleUntangling the Human Proteome